A Phase 2/3 interventional study of Gamma Knife VIM thalamotomy in Essential Tremor, sponsored by Université de Sherbrooke. Recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-17.
Sponsored by Université de Sherbrooke · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Essential Tremor with a site in Canada — 8 open to participants now, 11 under way, 1 of them phase 3. Essential Tremor · Canada.
Among the 26 studies in Essential Tremor with a site in Canada, this one is the 6th largest by planned enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2021, is the only one in phase 2/3, reaches primary completion later than 2 of the 10 other live ones, and was the 16th registered.
272 studies on the registry are indexed under Essential Tremor; 75 are open to participants now.
Browse Essential Tremor studies →8 of the 26 studies in Essential Tremor with a site in Canada are open now. Recruiting first, the newest first:
AbbVie · Sites in Canada, United States
Ages 18–85
University Health Network, Toronto · Sites in Canada
Ages 18–85 · Healthy volunteers
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 22+
Alfonso Fasano · Sites in Canada
Ages 18–85
University Health Network, Toronto · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 61 Essential Tremor studies recruiting now, 32 (52%) set no upper age limit and 5 (8%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 10 · Phase 3 1
First in 2006; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is above the median of 25 across 189 interventional studies indexed under Essential Tremor.
Median enrollment 22 across the 22 interventional studies, 370 across the 4 observational. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 26 have an industry lead sponsor. The 10 most frequent:
Université de Sherbrooke is the lead sponsor of 298 studies on the registry; 67 are open to participants now.
Université de Sherbrooke has 1 study filed under Essential Tremor — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Essential Tremor with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Combined Phase II/III, multi-center, prospective, single-blinded trial.
Ten (10) patients with essential tremor who previously underwent successful and uncomplicated GK thalamotomy for essential tremor will undergo a contralateral treatment. The incidence of side effects will be determined at 3 months postoperatively, graded per the CTCAE v5 and analyzed by a data safety monitoring board. Upon successful review, this Phase II trial will be converted to a Phase III trial of utility that will enrol 40 additional patients. The primary outcome will be the change in QUEST score at 12 months postoperatively, as well as a patient-reported assessment of Health Utility. Secondary outcomes will include objective tremor, gait and speech assessments (filmed and scored by blinded evaluators), as well as quality of life questionnaires and adverse events questionnaires. Outcomes will be assessed at baseline, as well as 3, 6, 12, 24 and 36 months post-operatively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo a thalamotomy contralateral to their previous treatment with Gamma Knife using a frame-based, Gamma Knife Perfexion or Icon unit (Elekta, Stockholm, Sweden).
Procedure: Gamma Knife VIM thalamotomy
Ablation of contralateral VIM nucleus of thalamus with GK using a frame-based, Gamma Knife Perfexion or Icon unit (Elekta, Stockholm, Sweden).
Change in QUEST Score
Difference in QUEST score between baseline and the 12-month follow-up, with statistical significance defined as p = 0.05 and a minimum clinically important difference (MCID) defined as 5
Time frame: 12 months
Patient-based Assessment of Utility
A patient-reported assessment of utility after 12 months using the question "Knowing what you know now, would you do this treatment again?".
Time frame: 12 months
Gait Assessment (NRS-11)
Patient-reported and blinded observer rating of the patient's ability to walk (Numerical rating scale (NRS-11) from 0 to 10, with 10 being best)
Time frame: Baseline, post operative month 3, 6, 12, 24, 36
Gait Assessment (missteps)
Number of missteps in a 6 m standardized tandem walk
Time frame: Baseline, post operative month 3, 6, 12, 24, 36
Falls
Number of falls in last month
Time frame: Baseline, post operative month 3, 6, 12, 24, 36
Speech Assessment (NRS-11)
Patient-reported and blinded observer rating of the patient's ability to speak (Numerical rating scale (NRS-11) from 0 to 10, with 10 being best)
Time frame: Baseline, post operative month 3, 6, 12, 24, 36
Numbness
Incidence of new-onset numbness
Time frame: Baseline, post operative month 3, 6, 12, 24, 36
Dysgeusia
Incidence of taste alterations
Time frame: Baseline, post operative month 3, 6, 12, 24, 36
Other adverse events
Incidence of other adverse events as classified in the CTCAE
Time frame: Baseline, post operative month 3, 6, 12, 24, 36
Tremor (CRST)
Assessment of tremor using the Clinical Rating Scale for Tremor (CRST) parts A (0-88) and B (0-36), higher scores correspond to a worse tremor).
Time frame: Baseline, post operative month 3, 6, 12, 24, 36
Quality of life (QUEST)
QUality of life in ESsential Tremor (QUEST) questionnaire (0-100 percent, higher scores correspond to a worse quality of life)
Time frame: Baseline, post operative month 3, 6, 12, 24, 36
Quality of life (CRST part C)
Part C of the Clinical Rating Scale for Tremor (CRST) (0-32, higher scores correspond to a worse quality of life)
Time frame: Baseline, post operative month 3, 6, 12, 24, 36
Health Utility (EQ-5D-5L)
Health Utility measured using the EQ-5D-5L and computed using the Canadian preference weights. Values range from 0 to 1, with 1 representing a perfect health.
Time frame: Baseline, post operative month 3, 6, 12, 24, 36
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2021 (actual). Primary completion is estimated for Feb 2026, 56 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.